With Aricept Losses Looming, Eisai Looks To Emerging Markets, Flexibility For New Growth

Eisai has grappled with the looming patent expiration of its blockbuster Alzheimer's disease drug Aricept, and the company has found a combination of efficiency models and belt-tightening - along with a pretty aggressive push to establish an oncology franchise - to realize growth after 2011